Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Aart Jan van der Lely(Erasmus University Rotterdam), Michael O. Thorner(Ames National Laboratory), Vivien Herman-Bonert(Cedars-Sinai Medical Center), Suzanne Hacker, Christian J. Strasburger(Humboldt-Universität zu Berlin), Paul M. Stewart(University of Leeds), Gudmundur Johannsson(Sahlgrenska University Hospital), Lawrence S. Phillips(Emory University), Kenneth Zib, Шломо Мелмед(Cedars-Sinai Medical Center), Ariel L. Barkan(University of Michigan), David R. Clemmons(University of North Carolina at Chapel Hill), Peter Trainer(University of Manchester), David M. Cook, Laurence Katznelson(Stanford University), Stavros Stavrou, R. Kent Hutson(University of Tennessee at Knoxville), Mary Lee Vance(University of Virginia), G. M. Besser(St Bartholomew's Hospital), Keith Friend(South Australia Pathology), Anne Klibanski(Mass General Brigham), John A. Scarlett(International Drug Development), Robert J. Davis(University of Verona), Pamela U. Freda(Columbia University)
Cited by 643
Related Papers
Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer
|New England Journal of Medicine|2006|985
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth
|Endocrine Reviews|2000|817
Selective oxidation of alcohols and aldehydes over supported metal nanoparticles
|Green Chemistry|2012|777